Statins and glycaemic control in individuals with diabetes: a systematic review and meta-analysis
Open accessThe DOI matches its Crossref record; 44 of the 45 references it cites were found in a registry or an index.
Abstract
Aims/hypotheses Current evidence indicates that statins increase the risk of incident diabetes; however, the relationship between statins and glycaemic control in people with established diabetes has not been well characterised. To address this question, we conducted a meta-analysis of randomised controlled trials (RCTs) of statins in patients with diabetes for whom there was available data on glycaemic control.Methods We identified studies published between January 1970 and November 2013 by searching electronic databases and reference lists. We included RCTs in which the intervention group received statins and the control group received placebo or standard treatment, with >200 participants enrolled, with the intervention lasting >12 weeks and with pre- and post-intervention HbA1c reported. We combined study-specific estimates using random-effects model meta-analysis.Results In a pooled analysis of nine trials involving 9,696 participants (4,980 statin, 4,716 control) and an average follow-up of 3.6 years, the mean HbA1c of participants randomised to statins was higher than those randomised to the control group: mean difference (95% CI) was 0.12% (0.04, 0.20) or 1.3 mmol/mol (0.4, 2.2); p = 0.003. There was moderate heterogeneity across the studies (I (2) = 54%, p = 0.014) not explained by available study-level characteristics. This review was limited by the small number of studies, available data on only three statins and sparse reporting on changes in use of glucose-lowering medications.Conclusions/interpretation Statin treatment is associated with a modest increase in HbA1c in patients with diabetes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“among patients with T2DM, the increase in glucose has also been shown to be rather modest, with an increase in mean glycated hemoglobin (HbA1c) level of 0.12% (95% CI, 0.04–0.20) over a mean follow-up of 3.6 years in a pooled analysis of 9 trials involving 9696 participants.119”
From Clinical management of stable coronary artery disease in patients with type 2 diabetes mellitus: a scientific statement from the American Heart Association (2020) · cites this paper as [119]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Measuring inconsistency in meta-analyses
Higgins, J. P. T., Thompson, S. G., Deeks, J. J., & Altman, D. G. (2003) · BMJ · doi:10.1136/bmj.327.7414.557 · Cited by 63,139 · cited 1×
“The I(2) statistic estimates the percentage of total variation across studies due to a true difference rather than chance [32].”
BackgroundBias in meta-analysis detected by a simple, graphical test
Egger, M., Smith, G. D., Schneider, M., & Minder, C. (1997) · BMJ · doi:10.1136/bmj.315.7109.629 · Cited by 56,722
Meta-analysis in clinical trials
DerSimonian, R., & Laird, N. (1986) · Controlled Clinical Trials · doi:10.1016/0197-2456(86)90046-2 · Cited by 39,552 · cited 1×
“We pooled the mean HbA1c difference across the studies (and subgroups) using random-effects model meta-analysis, which makes allowance for between-study heterogeneity [29].”
MethodQuantifying heterogeneity in a meta‐analysis
Higgins, J. P. T., & Thompson, S. G. (2002) · Statistics in Medicine · doi:10.1002/sim.1186 · Cited by 36,763 · cited 1×
“The Q statistic is the χ(2) test for heterogeneity with a degree of freedom equal to one minus the number of studies included in meta-analysis; this assesses whether observed differences in results between studies are due to chance alone [31].”
BackgroundAssessing the quality of reports of randomized clinical trials: Is blinding necessary?
Jadad, A. R., Moore, R. A., Carroll, D., Jenkinson, C., Reynolds, D. J. M., Gavaghan, D. J., & McQuay, H. J. (1996) · Controlled Clinical Trials · doi:10.1016/0197-2456(95)00134-4 · Cited by 17,582 · cited 1×
“The quality of the studies was assessed using US Preventive Task Force quality rating criteria for RCTs, the Jadad score [28].”
MethodDetection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III)
Grundy, S. M., Becker, D. M., Clark, L. T., Cooper, R., Denke, M. A., Howard, J. L., Hunninghake, D. B., Illingworth, D. R., Luepker, R. V., McBride, P. E., et al. (2002) · Civil War Book Review · Cited by 12,198
Stone, N. J., Robinson, J. G., Lichtenstein, A. H., Bairey Merz, C. N., Blum, C. B., Eckel, R. H., Goldberg, A. C., Gordon, D., Levy, D., Lloyd-Jones, D. M., et al. (2014) · Circulation · doi:10.1161/01.cir.0000437738.63853.7a · Cited by 7,081
Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein
Ridker, P. M., Danielson, E., Fonseca, F. A. H., Genest, J., Gotto, A. M., Kastelein, J. J. P., Koenig, W., Libby, P., Lorenzatti, A. J., MacFadyen, J. G., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0807646 · Cited by 6,674 · cited 1×
“3% for individuals randomised to rosuvastatin vs control [7, 36].”
BackgroundThe Emerging Risk Factors Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)60484-9 · Cited by 5,125
Cited by
Newman, C. B., Preiss, D., Tobert, J. A., Jacobson, T. A., Page, R. L., Goldstein, L. B., Chin, C., Tannock, L. R., Miller, M., Raghuveer, G., et al. (2019) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atv.0000000000000073 · Cited by 738
Sabatine, M. S., Leiter, L. A., Wiviott, S. D., Giugliano, R. P., Deedwania, P., De Ferrari, G. M., Murphy, S. A., Kuder, J. F., Gouni-Berthold, I., Lewis, B. S., et al. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30313-3 · Cited by 603
Arnold, S. V., Bhatt, D. L., Barsness, G. W., Beatty, A. L., Deedwania, P. C., Inzucchi, S. E., Kosiborod, M., Leiter, L. A., Lipska, K. J., Newman, J. D., et al. (2020) · Circulation · doi:10.1161/cir.0000000000000766 · Cited by 304
PCSK9: From Basic Science Discoveries to Clinical Trials
Shapiro, M. D., Tavori, H., & Fazio, S. (2018) · Circulation Research · doi:10.1161/circresaha.118.311227 · Cited by 285
Mancini, G. B. J., Baker, S., Bergeron, J., Fitchett, D., Frohlich, J., Genest, J., Gupta, M., Hegele, R. A., Ng, D., Pearson, G. J., et al. (2016) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2016.01.003 · Cited by 250
The diabetogenic action of statins — mechanisms and clinical implications
Betteridge, D. J., & Carmena, R. (2016) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2015.194 · Cited by 172
Cholesterol metabolism, pancreatic β-cell function and diabetes
Perego, C., Da Dalt, L., Pirillo, A., Galli, A., Catapano, A. L., & Norata, G. D. (2019) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2019.04.012 · Cited by 135
Management of dyslipidemia and atherosclerotic cardiovascular risk in prediabetes
Neves, J. S., Newman, C. B., Bostrom, J., Buysschaert, M., Newman, J. D., Medina, J. L., Goldberg, I. J., & Bergman, M. (2022) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2022.109980 · Cited by 99
Concurrent diabetes and heart failure: interplay and novel therapeutic approaches
Karwi, Q. G., Ho, K. L., Pherwani, S., Ketema, E. B., Sun, Q., & Lopaschuk, G. D. (2021) · Cardiovascular Research · doi:10.1093/cvr/cvab120 · Cited by 90
Lubaki, J.-P. F., Omole, O. B., & Francis, J. M. (2022) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-022-00902-0 · Cited by 87
Statins and risk of type 2 diabetes: mechanism and clinical implications
Laakso, M., & Fernandes Silva, L. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1239335 · Cited by 82
Leiter, L. A., Banach, M., Catapano, A. L., Duell, P. B., Gotto, A. M., Laufs, U., Mancini, G. B. J., Ray, K. K., Hanselman, J. C., Ye, Z., et al. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14645 · Cited by 74
Macrophage Heterogeneity and Plasticity: Impact of Macrophage Biomarkers on Atherosclerosis
Rojas, J., Salazar, J., Martínez, M. S., Palmar, J., Bautista, J., Chávez-Castillo, M., Gómez, A., & Bermúdez, V. (2015) · Scientifica · doi:10.1155/2015/851252 · Cited by 62
Tessari, P., & Lante, A. (2017) · Nutrients · doi:10.3390/nu9030297 · Cited by 72
“Although statins have been reported to exhibit deleterious effects on plasma glucose [32], plasma glucose was actually unchanged in the control group.”
BackgroundKim, J., Lee, H. S., & Lee, K. (2018) · Cardiovascular Diabetology · doi:10.1186/s12933-018-0799-4 · Cited by 64
Statin-induced diabetes: incidence, mechanisms, and implications
Ganda, O. P. (2016) · F1000Research · doi:10.12688/f1000research.8629.1 · Cited by 59
“In a meta-analysis of nine RCTs in 9696 patients with type 2 diabetes, with a mean follow-up of 3.6 years, there was a modest but significant increase in mean A1c level of 0.12% (95% CI 0.04–0.20) 23 .”
InfluentialMonami, M., Sesti, G., & Mannucci, E. (2019) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13599 · Cited by 58
Statins and diabetes: What are the connections?
Sattar, N. A. (2023) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2023.101749 · Cited by 57
Livingstone, S. J., Looker, H. C., Akbar, T., Betteridge, D. J., Durrington, P. N., Hitman, G. A., Neil, H. A. W., Fuller, J. H., & Colhoun, H. M. (2016) · Diabetologia · doi:10.1007/s00125-015-3802-6 · Cited by 46
“More recently, Erquo et al [9] combined treatment-arm means from published trials of those with diabetes, including unadjusted group means at 4 year follow-up, which we included as a safety analysis in the main results paper from CARDS [10].”
InfluentialZuo, Y., Chen, L., He, X., Ye, Z., Li, L., Liu, Z., & Zhou, S. (2021) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s298950 · Cited by 53
Feingold, K. R., & Grünfeld, C. (2023) · Contemporary cardiology · doi:10.1007/978-3-031-13177-6_14 · Cited by 50
Bruder-Nascimento, T. B., Callera, G. E., Montezano, A. C. I., He, Y., Antunes, T. T., Cat, A. N. D., Tostes, R. C., & Touyz, R. M. (2014) · Clinical Science · doi:10.1042/cs20140456 · Cited by 50
Sadighara, M., Amirsheardost, Z., Minaiyan, M., Hajhashemi, V., Naserzadeh, P., Salimi, A., Seydi, E., & Pourahmad, J. (2016) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.12656 · Cited by 50
Adenosine triphosphate citrate lyase: Emerging target in the treatment of dyslipidemia
Lemus, H. N., & Mendivil, C. O. (2015) · Journal of clinical lipidology · doi:10.1016/j.jacl.2015.01.002 · Cited by 50
Sympathetic Transduction in Type 2 Diabetes Mellitus: Impact of Statin Therapy
Young, B. E., Holwerda, S. W., Vranish, J. R., Keller, D. M., & Fadel, P. J. (2019) · Hypertension · doi:10.1161/hypertensionaha.119.12928 · Cited by 47
“Nevertheless, it is important to consider that statins may exert negative metabolic actions, which could further impair glycemic control in some patients with T2D.34,35 A more complete understanding of the mechanisms by which statin therapy reduces the exaggerated sympathetic transduction in T2D would provide valuable…”
BackgroundInfluentialHui-jin, W., Shang, H., & Wu, J. (2018) · Endocrine · doi:10.1007/s12020-018-1541-4 · Cited by 43
Sattar, N. A., Toth, P. P., Blom, D. J., Koren, M. J., Soran, H., Uhart, M., Elliott, M., Cyrille, M., Somaratne, R. M., & Preiss, D. (2017) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2017.07.047 · Cited by 42
“Although statin therapy is effective and safe, an adverse effect that has emerged in meta-analyses of major trials and studies of genetic polymorphisms is a modest increase in glycated hemoglobin (HbA1c) levels and the risk of developing diabetes.(2,3) It remains unclear whether this effect reflects the specific mecha…”
Yaluri, N., Modi, S., & Kokkola, T. (2016) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2016.10.026 · Cited by 41
“Statins also affect glycemic control in patients with pre-existing T2D [5].”
BackgroundSafety of Statins and Nonstatins for Treatment of Dyslipidemia
Newman, C. B. (2022) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2022.01.004 · Cited by 39
Adherence to statin therapy and the incidence of ischemic stroke in patients with diabetes
Korhonen, M. J., Ruokoniemi, P. T., Ilomäki, J., Meretoja, A., Helin‐Salmivaara, A., & Huupponen, R. (2015) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.3936 · Cited by 39
Exercise-Pharmacology Interactions: Metformin, Statins, and Healthspan
Miller, B. F., & Thyfault, J. P. (2020) · Physiology · doi:10.1152/physiol.00013.2020 · Cited by 33
Pharmacological management of diabetic dyslipidemia
Filippatos, T. D., Florentin, M., Georgoula, M., & Elisaf, M. (2016) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2017.1263565 · Cited by 33
“003) in diabetic patients with the use of statins compared with the control group [78].”
BackgroundThe effect of HIV infection on glycaemia and renal function in type 2 diabetic patients
Khoza, S. P., Crowther, N. J., & Bhana, S. (2018) · PLoS ONE · doi:10.1371/journal.pone.0199946 · Cited by 31
Statins may increase diabetes, but benefit still outweighs risk
Hoogwerf, B. J. (2023) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.90a.22069 · Cited by 29
“Erqou et al 28 performed a meta-analysis of 9 placebo-controlled trials of atorvastatin, simvastatin, and pravastatin.”
MethodCai, R., Yuan, Y., Sun, J. L., Xia, W., Huang, R., Tian, S., Dong, X., Shen, Y., & Wang, S. (2016) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2016.1220539 · Cited by 27
“Another meta-analysis conducted by Sebhat [11] showed that the mean serum HbA1c of patients assigned to statins is higher than that assigned to control.”
BackgroundMethodInfluentialMinaiyan, M., Sadighara, M., Joktaji, J., & Hajhashemi, V. (2017) · Research in Pharmaceutical Sciences · doi:10.4103/1735-5362.217424 · Cited by 26
“Although, the mechanisms of induction of diabetes with the consumption of statins have not been fully understood, published studies have indicated that one of the mechanisms of statin-induced diabetes is an increase in insulin resistance, which is reflected through hyperglycemia (34,35).”
BackgroundBays, H. E., Baum, S. J., Brinton, E. A., Plutzky, J., Hanselman, J. C., Teng, R., & Ballantyne, C. M. (2021) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2021.100278 · Cited by 25
Xu, L., Ran, J., Shao, H., Chen, M., Tang, H., Li, Y., Xu, Y., Huang, Y., Tao, F., Liu, Z., et al. (2025) · Diabetes Care · doi:10.2337/dc24-1699 · Cited by 19
Kim, Y.-S., Han, Y.-E., Choi, E.-A., You, N.-Y., Lee, J., You, H., Kim, Y., Kim, J., & Kang, H. (2019) · Primary care diabetes · doi:10.1016/j.pcd.2019.08.005 · Cited by 22
Chen, Q., Wu, G., Li, C., Qin, X., Liu, R., & Zhang, M. (2019) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-019-00386-w · Cited by 22
Managing dyslipidaemia in type 2 diabetes mellitus
Szalat, A., Durst, R. Y., & Leitersdorf, E. (2016) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2016.05.004 · Cited by 21
Albuquerque, E. L., Fulco, U. L., Caetano, E. W. S., & Freire, V. N. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108774956.011 · Cited by 21
Effect of high-potency statins on HbA1c in patients with or without diabetes mellitus
Ooba, N., Tanaka, S., Yasukawa, Y., Yoshino, N., Hayashi, H., Hidaka, S., Seki, T., & Fukuoka, N. (2016) · Journal of Pharmaceutical Health Care and Sciences · doi:10.1186/s40780-016-0040-0 · Cited by 21
“The results of a meta-analysis on statins and glycemic control [7] and the findings of several other studies in patients with diabetes [14–16] suggest that statin treatment is associated with a modest increase in HbA1c.”
BackgroundResultUnexplained reciprocal regulation of diabetes and lipoproteins
Higuchi, S., Izquierdo, M. C., & Haeusler, R. A. (2018) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000521 · Cited by 20
Anyanwagu, U., Mamza, J., Donnelly, R., & IDRIS, I. R. (2017) · Cardiovascular Diabetology · doi:10.1186/s12933-017-0587-6 · Cited by 19
“heterogeneity of effect among the different statins [15].”
BackgroundInfluentialCardiovascular outcomes trials with statins in diabetes
Naeem, F., McKay, G. A., & Fisher, M. (2018) · British Journal of Diabetes · doi:10.15277/bjd.2018.161 · Cited by 19
Dijk, W., & Cariou, B. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13636 · Cited by 19
Jensen, M. T., Andersen, H. U., Rossing, P. R., & Jensen, J. S. (2015) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2015.10.022 · Cited by 18
A dysglycaemic effect of statins in diabetes: relevance to clinical practice?
Swerdlow, D. I., & Sattar, N. A. (2014) · Diabetologia · doi:10.1007/s00125-014-3409-3 · Cited by 18
Simvastatin Rapidly and Reversibly Inhibits Insulin Secretion in Intact Single-Islet Cultures
Scattolini, V., Luni, C., Zambon, A., Galvanin, S., Gagliano, O., Ciubotaru, C. D., Avogaro, A., Mammano, F., Elvassore, N., & Fadini, G. P. (2016) · Diabetes Therapy · doi:10.1007/s13300-016-0210-y · Cited by 17
“suggest that statins may increase the risk of developing diabetes by acting on insulin secretion, insulin resistance, or both [11, 12, 35, 36].”
BackgroundYang, G., & Schooling, C. M. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac562 · Cited by 17
Do Statins Counteract the Effect of Antidiabetic Drugs? Results of the SCEAD Study
Tarım, B. A., Fıcı, F., Tengiz, İ., Avunduk, S., Ozcan, Y., Faikoğlu, G., Arı, E., Robles, N. R., & Grassi, G. M. (2023) · Yonsei Medical Journal · doi:10.3349/ymj.2022.0287 · Cited by 17
“These conflicting findings have been properly highlighted in recent systematic reviews.(20,22-24) Among statins, moderate/high daily doses of atorvastatin and rosuvastatin have been shown to be associated with dysregulation of glucose homeostasis in patients with or without T2DM.”
BackgroundResultLa diabetogenicidad de las estatinas: ¿son todas iguales? Estado de la cuestión
Tarruella, J. R., Núñez-Cortés, J. M., Pedro‐Botet, J., & Pintó, X. (2015) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/j.arteri.2015.02.001 · Cited by 16
“36 HbA .”
Thongtang, N., Tangkittikasem, N., Samaithongcharoen, K., Piyapromdee, J., Srinonprasert, V., & Sriussadaporn, S. (2020) · Vascular Health and Risk Management · doi:10.2147/vhrm.s270751 · Cited by 16
“Worsened glucose control in T2D was also reported in statin users compared to those that did not use statin.(10) Another study reported a significant increase in HbA1c from baseline of 0.”
BackgroundResultInfluentialSingh, P., Gonçalves, I., Tengryd, C., Nitulescu, M., Persson, A. F., To, F., Bengtsson, E., Volkov, P., Orho‐Melander, M., Nilsson, J. Å., et al. (2020) · Cardiovascular Diabetology · doi:10.1186/s12933-020-01189-z · Cited by 16
Shin, K.-H., & Choi, H. D. (2022) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-021-00516-3 · Cited by 12
Sugawara, J. (2005) · PubMed · Cited by 15
Preventing Diabetes and Atherosclerosis in the Cardiometabolic Syndrome
Ahmad, M. I., & Shapiro, M. D. (2021) · Current Atherosclerosis Reports · doi:10.1007/s11883-021-00913-8 · Cited by 14
Lee, J.-E., Yu, S. H., Kim, S. R., Ahn, K. J., Song, K., Lee, I., Shon, H., Kim, I. J., Lim, S. K., Kim, D. M., et al. (2024) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2023.0077 · Cited by 13
Self-citationZenti, M. G., Rubbo, I., Ceradini, G., Rinaldi, E., Nadalini, L., Battistoni, M., Genna, M., Bonora, E., & Zoppini, G. (2015) · Acta Diabetologica · doi:10.1007/s00592-015-0738-8 · Cited by 13
Bardini, G., Giannini, S., Rotella, C. M., Pala, L., Cresci, B., & Mannucci, E. (2016) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2016.07.015 · Cited by 13
A sequence symmetry analysis of the interrelationships between statins, diabetes and skin infections
Ko, H. H. T., Lareu, R. R., Dix, B. R., Hughes, J., & Parsons, R. W. (2019) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14077 · Cited by 13
Roussel, R., Chaignot, C., Weill, A., Travert, F., Hansel, B., Marre, M., Ricordeau, P., Alla, F., & Allemand, H. (2015) · PLoS ONE · doi:10.1371/journal.pone.0137733 · Cited by 13
Bae, J. C., Min, K. W., Kim, Y. H., Kim, K., Hong, E., Park, C., Han, S. Y., & Cha, B. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13491 · Cited by 12
“5% higher than that of participants randomized to the control group at the end of follow-up.(22) ROSU (20 mg), which was used in our study, is a high-potency statin,(18) and the difference in HbA1c (0.”
MethodEfficacy and Safety of PCSK9 Monoclonal Antibodies in Patients With Diabetes
Marouf, B. H., Iqbal, Z., Mohamad, J. B., Bashir, B., Schofield, J. D., Syed, A. A., Kilpatrick, E. S., Stefanutti, C., & Soran, H. (2022) · Clinical Therapeutics · doi:10.1016/j.clinthera.2021.12.005 · Cited by 12
Pitavastatin and carbohydrate metabolism: what is the evidence?
Filippatos, T. D., & Elisaf, M. (2016) · Expert Review of Clinical Pharmacology · doi:10.1586/17512433.2016.1165607 · Cited by 12
The utility of ezetimibe therapy in nonalcoholic fatty liver disease
Jun, B. G., & Cheon, G. J. (2019) · The Korean Journal of Internal Medicine · doi:10.3904/kjim.2019.043 · Cited by 12
“Ezetimibe treatment poses a risk of new-onset diabetes and increased HbA1c levels [12].”
BackgroundStatin Use and Hyperglycemia: Do Statins Cause Diabetes?
Bredefeld, C., Choi, P., Cullen, T., Nicolich-Henkin, S., & Waters, L. (2024) · Current Atherosclerosis Reports · doi:10.1007/s11883-024-01266-8 · Cited by 11
Baul, P. B., Deepak, A. D., Kakkar, M., & Modi, S. (2020) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2020.07.020 · Cited by 11
Feingold, K. R. (2020) · Europe PMC (PubMed Central) · Cited by 11
Jiao, B., Wang, B., Liu, B., Zhao, J., & Zhang, Y. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1468476 · Cited by 10
“Therefore, from studies, con fl icting evidence exists (60).”
BackgroundHirano, T., Hayashi, T., Sugita, H., Tamasawa, A., Goto, S., Tomoyasu, M., Yamamoto, T., Ohara, M., Terasaki, M., Kushima, H., et al. (2023) · Journal of Diabetes Investigation · doi:10.1111/jdi.14076 · Cited by 10
“A previous study reported bene fi cial effects of fi brates on glycemic control in patients with type 2 diabetes 30 , whereas statins are shown to be associated with increased risks for type 2 diabetes patients 31 .”
BackgroundResultDavis, T. M. E., Badshah, I., Chubb, S. A. P., & Davis, W. A. (2016) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12710 · Cited by 10
“3 mmol/mol).(3) Taken together, these data provide evidence that the initiation of low-/moderate-intensity statin treatment does not usually have a clinically meaningful impact on glycaemic control; 1144 DAVIS ET AL.”
BackgroundHammad, M. A., Abdo, M. S., Mashaly, A. M., Sulaiman, S. A. S., Alghamdi, S., Mangi, A. A., & Noor, D. A. M. (2019) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2019.07.005 · Cited by 10
Domecq, J. P., Prutsky, G. J., Elraiyah, T. A., Wang, Z., Mauck, K. F., Brito, J. P., Undavalli, C., Sundaresh, V., Prokop, L. J., Montori, V. M., et al. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2019-01269 · Cited by 8
Milajerdi, A., Sadeghi, A., Mousavi, S. M., Larijani, B. A., & Esmaillzadeh, A. (2020) · Clinical Therapeutics · doi:10.1016/j.clinthera.2019.12.009 · Cited by 7
Wu, Z., Chen, S., Tao, X., Liu, H., Sun, P., Richards, M., Tan, H. C., Yu, Y., Yang, Q., Wu, S., et al. (2024) · Clinical Research in Cardiology · doi:10.1007/s00392-024-02381-x · Cited by 7
“Moreover, a meta-analysis of nine RCTs demonstrated that statin therapy was associated with a mild increase in glycated hemoglobin (HbA1c) in patients with diabetes [9].”
InfluentialSarkar, S., Orimoloye, O. A., NASS, C. M., Blumenthal, R. S., & Martin, S. S. (2019) · Journal of General Internal Medicine · doi:10.1007/s11606-019-05266-2 · Cited by 7
Hori, E., Kikuchi, C., Imaeda, K., Okayama, N., Suzuki, T., & Matsunaga, T. (2019) · YAKUGAKU ZASSHI · doi:10.1248/yakushi.18-00218 · Cited by 6
Wood, S. J., Magliano, D. J., Bell, J. S., Shaw, J. E., & Ilomäki, J. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.794273 · Cited by 5
“However, statin use has only been associated with modest glycaemic changes (Erqou et al., 2014).”
BackgroundStatin use and incident type 2 diabetes mellitus in women after menopause
Anelli, V., Armeni, E., Paschou, S. Α., & Lambrinoudaki, I. V. (2024) · Maturitas · doi:10.1016/j.maturitas.2024.107914 · Cited by 5
Statin and the risk of new-onset diabetes mellitus
Kim, S. (2017) · Journal of Korean Medical Association · doi:10.5124/jkma.2017.60.11.901 · Cited by 5
Role of Glucose and Lipids in the Atherosclerotic Cardiovascular Disease of Patients with Diabetes
Feingold, K. R. (2020) · Europe PMC (PubMed Central) · Cited by 5
Hammad, M. A., Noor, D. A. M., Sulaiman, S. A. S., Khamis, A. A., Kharshid, A. M., & Aziz, N. A. (2017) · Zenodo (CERN European Organization for Nuclear Research) · doi:10.5281/zenodo.1131680 · Cited by 4
Statins associated diabetes: state of the problem in 2018
Kobalava, Z. D., Lazarev, P. V., & Вадимовна, В. С. (2018) · Russian Cardiology Journal (Russian Cardiology Society) · doi:10.15829/1560-4071-2018-9-89-99 · Cited by 4
Statins Reduce Delirium Risk in Older Adults With Type 2 Diabetes
Sun, M., Wang, X., Lu, Z., Yang, Y., Lv, S., Miao, M., Chen, W., Wu, S., & Zhang, J. (2025) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2025.105490 · Cited by 3
Deng, B., Li, S., You, R., & Fu, Z. (2024) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2024.2418325 · Cited by 3
“Prior meta-analyses have indeed suggested that ator-vastatin and rosuvastatin may confer higher diabetes hazards compared to other statins [38,39].”
Treatment of Patients Chronic Coronary Heart Disease and Type 2 Diabetes Mellitus
Shchukina, E. V. S., Приколота, О. А., Bagriy, V. A., Андрусяк, А. Ю., Gs, R., Shesterina, Y. B., & Stefano, E. (2023) · The Russian Archives of Internal Medicine · doi:10.20514/2226-6704-2023-13-2-97-109 · Cited by 3
Do statins adversely affect the HbA1c of diabetic patients?
Son, W. D., & Teng, C. L. (2017) · Europe PMC (PubMed Central) · Cited by 3
Furtado, R. H. D. M., Genestreti, P., Dalçóquio, T. F., Baracioli, L., Lima, F. G., Franci, A., Giraldez, R. R., Menezes, F. R., Ferrari, A., Lima, V. M., et al. (2021) · Arquivos Brasileiros de Cardiologia · doi:10.36660/abc.20200128 · Cited by 3
“CABG prévia 327 (13,9) 234 (13,7) 93 (14,2) 0,75”
Role of Statins in Glucose Homeostasis and Insulin Resistance
Dahagam, C., Hahn, V. S., Goud, A., D’Souza, J., Abdelqader, A., Blumenthal, R. S., & Martin, S. S. (2016) · Current Cardiovascular Risk Reports · doi:10.1007/s12170-016-0523-4 · Cited by 2
“Based on data from large randomized trials, it was estimated that a reduction in LDL-C by 2 mmol/L (77 mg/dL) would lead to a 10 % absolute benefit in secondary prevention in patients with established ASCVD and a 5 % absolute benefit in patients being treated for primary prevention of ASCVD over the course of 5 years…”
BackgroundInfluentialFu, L., Zhang, Y., Du, X., Han, R., Hu, R., Anderson, C. S., Ji, L., & Ma, C. (2024) · Cardiovascular Innovations and Applications · doi:10.15212/cvia.2024.0010 · Cited by 2
Analysis of Safety Issues of Using Statins in Patients with Diabetes and Hypothyroidism
Arkhipov, V. V., Gorodetskaya, G. I., Демидова, О. А., Alexandrova, T. V., & Alexandrov, A. A. (2019) · Safety and Risk of Pharmacotherapy · doi:10.30895/2312-7821-2019-7-4-163-175 · Cited by 2
Statins and Diabetes: The Plot Thickens
Gastaldi, G., & Philippé, J. (2015) · Journal of General Internal Medicine · doi:10.1007/s11606-015-3399-y · Cited by 2
“2 % in patients randomized to statin versus control treatment.(5) This dysglycemic effect of statins is apparently due to a reduction in both insulin sensitivity and secretion.”
BackgroundCassenote, A. J. F. (2017) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.5.2017.tde-14122017-112914 · Cited by 2
Ganesan, S., More, B. D., Gnansegaran, S., Anandan, I., Selvaraj, N., & Mohanasundaram, J. (2023) · National Journal of Laboratory Medicine · doi:10.7860/njlm/2023/58502.2689 · Cited by 1
Maideen, N. M. P., Jumale, A. H., Albasti, A. K., Kadir, D. A. A., Alkhawalda, M. Y., Shokr, A. F., & Canani, M. (2026) · Cardiovascular & Haematological Disorders - Drug Targets · doi:10.2174/011871529x429107251202110301 · Cited by 1
Fariba, F., Akhavan, M., & Rabee, M. S. (2018) · Electronic Journal of General Medicine · doi:10.29333/ejgm/93474 · Cited by 1
How has the treatment of hypercholesterolemia in Poland changed over the last six years?
Kapłon‐Cieślicka, A., Michalak, M., Kołtowski, Ł., & Filipiak, K. J. (2017) · Cardiology Journal · doi:10.5603/cj.a2017.0047 · Cited by 1
Lipid modification in people with diabetes
Morris, D. (2023) · Prescriber · doi:10.1002/psb.2053 · Cited by 1
Metadata
- Authors
- Erqou, S., Lee, C. C., & Adler, A. I.
- Affiliations
- Weill Cornell Medicine (US)
- University of Toronto (CA)
- Addenbrooke's Hospital (GB)
- Corresponding author
- Erqou, Sebhat
- Venue
- Diabetologia
- Published
- 2014-09-23
- Volume
- 57
- Issue
- 12
- Pages
- 2444-2452
- ISSN
- 0012-186X (ISSN-L)
- 1432-0428
- OpenAlex
- W2140272923
- Cited by
- 126
- References
- 45
- Citations by year
- 2026: 5 · 2025: 4 · 2024: 8 · 2023: 11 · 2022: 16 · 2021: 8 · 2020: 10 · 2019: 14 · 2018: 10 · 2017: 9 · 2016: 14 · 2015: 13 · 2014: 2
- FWCI
- 2.39
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Diabetologia (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Weill Cornell Medical College
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
- Keywords
- statins, diabetes mellitus, glycemic control, HbA1c, hyperglycemia, glucose-lowering medications, lipid-lowering therapy
- MeSH terms
- Blood Glucose, Diabetes Mellitus, Humans, Hydroxymethylglutaryl-CoA Reductase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.